- Home
- ACRS vs GGZ Comparison
ACRS vs GGZ Comparison
Compare ACRS & GGZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- GGZ
- Stock Information
- Founded
- ACRS 2012
- GGZ 2013
- Country
- ACRS United States
- GGZ United States
- Employees
- ACRS N/A
- GGZ N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- GGZ Investment Managers
- Sector
- ACRS Health Care
- GGZ Finance
- Exchange
- ACRS Nasdaq
- GGZ Nasdaq
- Market Cap
- ACRS 137.5M
- GGZ 105.1M
- IPO Year
- ACRS 2015
- GGZ N/A
- Fundamental
- Price
- ACRS $1.46
- GGZ $12.98
- Analyst Decision
- ACRS Strong Buy
- GGZ
- Analyst Count
- ACRS 8
- GGZ 0
- Target Price
- ACRS $9.71
- GGZ N/A
- AVG Volume (30 Days)
- ACRS 709.4K
- GGZ 12.8K
- Earning Date
- ACRS 05-08-2025
- GGZ 01-01-0001
- Dividend Yield
- ACRS N/A
- GGZ 5.39%
- EPS Growth
- ACRS N/A
- GGZ N/A
- EPS
- ACRS N/A
- GGZ 1.75
- Revenue
- ACRS $17,777,000.00
- GGZ N/A
- Revenue This Year
- ACRS N/A
- GGZ N/A
- Revenue Next Year
- ACRS $14.59
- GGZ N/A
- P/E Ratio
- ACRS N/A
- GGZ $6.79
- Revenue Growth
- ACRS N/A
- GGZ N/A
- 52 Week Low
- ACRS $0.99
- GGZ $9.43
- 52 Week High
- ACRS $5.17
- GGZ $12.50
- Technical
- Relative Strength Index (RSI)
- ACRS 61.33
- GGZ 65.90
- Support Level
- ACRS $1.22
- GGZ $12.73
- Resistance Level
- ACRS $1.56
- GGZ $13.09
- Average True Range (ATR)
- ACRS 0.09
- GGZ 0.24
- MACD
- ACRS 0.03
- GGZ -0.01
- Stochastic Oscillator
- ACRS 75.00
- GGZ 35.88
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About GGZ Gabelli Global Small and Mid Cap Value Trust (The) of Beneficial Interest
The Gabelli Global Small and Mid Cap Value Trust is a diversified closed-ended management investment company whose investment objective is long-term capital growth. It invests in equity securities such as common stock and preferred stock of companies.